Reprogramming the Immune Landscape of Inflammatory Breast Cancer
Advanced Science · 2026-06 · 13 (36)
DOI: 10.1002/advs.75766 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 23.05.2026. Verfasst von Verena Martinez-Rodriguez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii, USA. Hauptthemen laut MEDLINE: Inflammatory Breast Neoplasms, Tumor Microenvironment, Immunotherapy. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Research Foundation grant, NCI NIH HHS, NIH/NCI.
Abstract (Originalsprache)
Inflammatory breast cancer (IBC) is the most aggressive subtype of breast cancer, characterized by rapid progression, early metastasis, and profound therapeutic resistance. Despite advances in multimodal therapy, outcomes remain poor, emphasizing the need for novel treatment strategies. Increasing evidence reveals that IBC exhibits an immunosuppressive tumor microenvironment (TME), driven by interactions among tumor cells and TME components that promote immune evasion through cytokine signaling loops, immune checkpoint overexpression, and formation of tumor emboli that shield cancer cells from immune surveillance. Recent multi‐omics and spatial transcriptomic studies reveal extensive immune heterogeneity, with both “immune‐hot” and “immune‐cold” niches influencing responses to immunotherapy. Clinical trials testing immune checkpoint inhibitors alone or combined with chemotherapy, antibody–drug conjugates, or targeted therapy show early promise but remain limited by small IBC cohorts and inconsistent diagnostic criteria. Integrating immune biomarkers, including PD‐L1 expression, tumor mutational burden, T‐cell clonality, and spatial immune signatures, may improve patient stratification and therapeutic precision. This review summarizes mechanistic and clinical insights defining IBC immunobiology, highlights barriers to durable immune activation, and outlines strategies to reprogram the TME toward an immunoactive state. Advancing combination immunotherapy and adaptive clinical trial designs through global collaboration will be essential to improve outcomes for IBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii, USA.
- University of Hawai'i Inflammatory Breast Cancer Clinic and Research Program, Honolulu, Hawaii, USA.
Förderung
- Breast Cancer Research Foundation grant
- NCI NIH HHS
- NIH/NCI
- U.S. Department of Defense
- Hawai'i Community Foundation
- NIH grant
Zitieren
APA
Martinez-Rodriguez, V., Ogata, S., Wang, X., & Ueno, N. T. (2026). Reprogramming the Immune Landscape of Inflammatory Breast Cancer. Advanced Science, 13(36). https://doi.org/10.1002/advs.75766
Vancouver
Martinez-Rodriguez V, Ogata S, Wang X, Ueno NT. Reprogramming the Immune Landscape of Inflammatory Breast Cancer. Advanced Science. 2026;13(36). doi:10.1002/advs.75766
BibTeX
@article{MartinezRodriguez2026,
author = {Martinez-Rodriguez, Verena and Ogata, Suguru and Wang, Xiaoping and Ueno, Naoto T},
title = {Reprogramming the Immune Landscape of Inflammatory Breast Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {36},
doi = {10.1002/advs.75766}
}
EUVIMED